Literature DB >> 27276701

Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

Luca Valenti1,2, Elisabetta Bugianesi3, Utpal Pajvani4, Giovanni Targher5.   

Abstract

Growing epidemiological evidence suggests that nonalcoholic fatty liver disease (NAFLD) is an early predictor of and determinant for the development of type 2 diabetes and other features of the metabolic syndrome. This finding may have important clinical implications for the diagnosis, prevention and treatment of type 2 diabetes and its chronic complications. However, given the complex and bi-directional relationships between NAFLD, insulin resistance and chronic hyperglycaemia, it is extremely difficult to distinguish whether NAFLD is a cause or a consequence of insulin resistance and type 2 diabetes. Indeed, at the molecular level, hepatic lipogenesis and hepatic glucose production depend on differentially regulated branches of the insulin signalling pathway. Furthermore, genetic studies suggest that excess hepatic fat is associated with progressive liver disease, but does not always increase the risk of incident type 2 diabetes. Here, we will briefly review the epidemiological, pathophysiological and molecular evidence linking NAFLD to the development of type 2 diabetes. We will also discuss some recent genetic and therapeutic advances that seem to challenge a causal role of NAFLD in the pathogenesis type 2 diabetes, and propose a working hypothesis to explain this apparent conundrum. In conclusion, progressive liver disease and type 2 diabetes are divergent though inter-related consequences of insulin resistance and the metabolic syndrome.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genetics; insulin resistance; nonalcoholic fatty liver disease; pathophysiology; type 2 diabetes

Mesh:

Substances:

Year:  2016        PMID: 27276701     DOI: 10.1111/liv.13185

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  44 in total

Review 1.  Multiorgan, Multimodality Imaging in Cardiometabolic Disease.

Authors:  Vidhya Kumar; Willa A Hsueh; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2017-11       Impact factor: 7.792

2.  Polychlorinated biphenyl exposures differentially regulate hepatic metabolism and pancreatic function: Implications for nonalcoholic steatohepatitis and diabetes.

Authors:  Hongxue Shi; Jian Jan; Josiah E Hardesty; K Cameron Falkner; Russell A Prough; Appakalai N Balamurugan; Sri Prakash Mokshagundam; Suresh T Chari; Matthew C Cave
Journal:  Toxicol Appl Pharmacol       Date:  2018-10-09       Impact factor: 4.219

Review 3.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

4.  Associations of Insulin Resistance and Glycemia With Liver Enzymes in Hispanic/Latino Youths: Results From the Hispanic Community Children's Health Study/Study of Latino Youth (SOL Youth).

Authors:  Christina M Parrinello; Bryan J Rudolph; Mariana Lazo; Linda C Gallo; Bharat Thyagarajan; Scott J Cotler; Qibin Qi; Tossaporn Seeherunvong; Denise C Vidot; Howard D Strickler; Robert C Kaplan; Carmen R Isasi
Journal:  J Clin Gastroenterol       Date:  2019-02       Impact factor: 3.062

5.  PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients.

Authors:  Paola Dongiovanni; Marica Meroni; Guido Baselli; Rosellina M Mancina; Massimiliano Ruscica; Miriam Longo; Raffaela Rametta; Annalisa Cespiati; Serena Pelusi; Nicola Ferri; Valeria Ranzani; Valerio Nobili; Jussi Pihlajamaki; Anna Ludovica Fracanzani; Sara Badiali; Salvatore Petta; Silvia Fargion; Stefano Romeo; Julia Kozlitina; Luca Valenti
Journal:  J Lipid Res       Date:  2019-03-27       Impact factor: 5.922

6.  Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

Authors:  KyeongJin Kim; Dongryeol Ryu; Paola Dongiovanni; Lale Ozcan; Shruti Nayak; Beatrix Ueberheide; Luca Valenti; Johan Auwerx; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2017-08-30       Impact factor: 22.682

7.  Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA).

Authors:  Luis A Rodriguez; Alka M Kanaya; Stephen C Shiboski; Alicia Fernandez; David Herrington; Jingzhong Ding; Patrick T Bradshaw
Journal:  Ann Epidemiol       Date:  2021-07-19       Impact factor: 3.797

Review 8.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

9.  High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects.

Authors:  Yukimura Higashiura; Masato Furuhashi; Marenao Tanaka; Satoko Takahashi; Masayuki Koyama; Hirofumi Ohnishi; Keita Numata; Takashi Hisasue; Nagisa Hanawa; Norihito Moniwa; Kazufumi Tsuchihashi; Tetsuji Miura
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

10.  Association of hepatic steatosis derived from ultrasound and quantitative MRI with prediabetes in the general population.

Authors:  Till Ittermann; Henry Völzke; Muhammad Naeem; Robin Bülow; Sabine Schipf; Nicole Werner; Marcus Dörr; Markus M Lerch; Jens-Peter Kühn; Wolfgang Rathmann; Matthias Nauck; Marcello Ricardo Paulista Markus
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.